1569P A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 infection optionally treated with granulocyte colony-stimulating factor (G-CSF): A comparative analysis

M Sereno Moyano,G Colmenarejo,J Baena,C Aguado De La Rosa,X Mielgo,A Pertejo,R Alvarez Alvarez,A Sánchez,J.L López,R Molina,A Lopez-Alfonso,B Hernandez,L.E Chiara Velarde,A.M Martin,A López Martin,M Dorta Suarez,A Collazo,E Casado,A Jimenez Gordo

doi:10.1016/j.annonc.2021.08.1562

Abstract

SARS-CoV-2 infection can induce a host hyperinflammatory response induced by a cytokine storm, that is the main cause of mortality. Myelosuppression is associated with higher risk of infections and mortality. Few reports have addressed about the management of patients with neutropenia and COVID-19. Herein, we present a retrospective study during COVID-19 outbreak in neutropenic cancer patients with COVID-19 comparing the outcome and survival between G-CSF treated vs G-CSF non-treated group.

Full Text